Efor news
2/04/2026
Nitrosamine Impurities in Pharmaceuticals: Chemistry, Evolving Regulations and Strategic Risk Control
Nitrosamines are highly reactive, potentially DNA-damaging chemicals
26/03/2026
Efor strengthens its U.S. presence with a new office in Houston
Efor is continuing its expansion in North America with the opening of a new office in Houston, Texas.
19/03/2026
Reimbursement of Health Products in France: A Public-Health and Market-Access Issue
This article provides a concise overview of the reimbursement dossier journey, outlining its stakes, the key stakeholders involved
12/03/2026
International Women’s Day: Celebrating the women who shape Efor
On the occasion of International Women’s Day, Efor celebrates the women who contribute every day to our collective success.
5/03/2026
No Deviation joins Efor, strengthening our presence in Asia
Efor welcomes No Deviation, a Singapore based company recognized for its expertise in CQV, CSV, Quality Compliance, and Digit
Join our team
Consult our offers
5/03/2026
The Talc Debate: Health Risks and Controversies
A seemingly harmless natural mineral, talc has once again become the focus of a major public-health debate in 2025
4/03/2026
DynamixE joins Efor, strengthening our execution platform in North America
This is not a “day one” relationship. Efor and DynamixE teams are already collaborating on several large US projects, with ali
26/02/2026
Efor successfully completes a €300m refinancing to support its international growth strategy
Efor announces the refinancing of its existing debt for an amount of approximately €300 million.
19/02/2026
Post-Marketing Authorisation Variations: The changing European regulatory landscape, from regulation to guidance
As of 15 January 2026, the European framework for managing post-marketing authorisation (MA) variations for human medicinal produc
11/02/2026
Women in Science: Inspiring Journeys at Efor
On February 11th, the world celebrates the International Day of Women and Girls in Science.
5/02/2026
Risk-Based Monitoring and the impact of ICH E6 (R3) on clinical trials
Revision 3 of the Good Clinical Practice guideline (ICH E6 [R3]) was adopted on 6 January 2025 and will take effect on 23 July 202
29/01/2026
Efor expands in Italy with the opening of a Milan office
Efor continues its international expansion with a new strategic milestone: the launch of a new office in Milan, Italy.
